Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
147,179,178
-
Number of holders
-
208
-
Total 13F shares, excl. options
-
115,037,875
-
Shares change
-
+2,160,020
-
Total reported value, excl. options
-
$2,465,293,115
-
Value change
-
+$48,272,802
-
Put/Call ratio
-
82%
-
Number of buys
-
99
-
Number of sells
-
88
-
Price
-
$21.46
Institutional Holders of Denali Therapeutics Inc. - COMMON STOCK (DNLI) as of Q4 2023
As of 31 Dec 2023 Denali Therapeutics Inc. - COMMON STOCK (DNLI) had 208 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 115,037,875 shares of stock of the company.
Largest 10 holders included BAILLIE GIFFORD & CO, BlackRock Inc., VANGUARD GROUP INC, WELLINGTON MANAGEMENT GROUP LLP, Temasek Holdings (Private) Ltd, Crestline Management, LP, STATE STREET CORP, TAKEDA PHARMACEUTICAL CO LTD, Capital Research Global Investors, and GEODE CAPITAL MANAGEMENT, LLC.
This table shows 208 institutional shareholders of the security as of 31 Dec 2023.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.